论文部分内容阅读
评价唯地息用于干眼症的临床疗效。方法 :将 10 1例干眼症患者随机分为唯地息治疗组 ( 5 2例 75眼 )及素高捷疗对照组 ( 49例 70眼 ) ,观察两组的治疗效果。结果 :治疗组有 34眼显效占 45 % ,41眼好转占 5 5 % ,总有效率 10 0 % ;对照组 2 3眼显效占 33% ,47眼好转占 6 7% ,总有效率 10 0 %。两组显效率与好转率无显著差异。治疗组有 2例发生不良反应 ,对照组有 6例发生不良反应 ,两组的不良反应发生率不存在差异。结论 :唯地息凝胶是一种安全有效的新型人工泪液制剂
Evaluation of the only interest for the clinical efficacy of dry eye syndrome. Methods: One hundred and ten patients with dry eye were randomly divided into treatment group (52 cases, 75 eyes) and control group (49 cases, 70 eyes). The therapeutic effects of the two groups were observed. Results: In the treatment group, the effective rate of 34 eyes was 45%, that of 41 eyes was 55%, and the total effective rate was 100%. In the control group, the effective rate of 33 eyes was 33%, that of 47 eyes was 67%, and the total effective rate was 10% %. There was no significant difference between the two groups in apparent efficiency and improvement rate. There were 2 adverse reactions in the treatment group, 6 adverse reactions in the control group, and no difference in adverse reactions between the two groups. Conclusion: Verogel is a safe and effective new artificial tear preparation